Cervical Cancer

Cytokines and CD80 Enhance Immunogenicity of Cell Vaccine

Published in Vaccine Weekly, January 31st, 2001

Tumor cells genetically altered to express CD80 and certain interleukins (IL) can be used to enhance the efficacy of tumor vaccines against cervical cancer, according to a recent study.

"Tumor cells fail to activate specific cytotoxic T lymphocytes due to lack of co-stimulatory molecules, e.g., CD80 (B7.1)," stated A.M. Kaufmann and colleagues, Loyola University, Illinois. "We were able to render cervical carcinoma cells immunogenic by introduction of the CD80 gene into the tumor cells. In order to enhance the efficiency of T-cell activation we investigated whether addition of interleukins would augment immunostimulation by CD80."

Kaufmann et al....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-01-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry